Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 789-797

  Zhou, Pengfei ^a,b   Qiu, Junzhuan ^a   L'Italien, Lawrence ^a   Gu, Danling ^a   Hodges, Douglas ^a   Chao, Cheng Chi ^a   Schebye, Xiao Min ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Crown Bioscience Inc   (China)

Author keywords

B cell and T cell; CTLA 4 OX40; GITR; JHD mouse; tumor immunotherapy

Indexed keywords

CD69 ANTIGEN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DTA 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD40; B-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES;

EID: 77958038643     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ee6ba9     Document Type: Article

References (46)

1. Waldmann TA. Effective cancer therapy through immuno-modulation. Annu Rev Med. 2006;57:65-81.
2. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269-279.
3. Xiao H, Huang B, Yuan Y, et al. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res. 2007;13:1823-1830.
4. May KF Jr, Chen L, Zheng P, et al. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002;62:3459-3465.
5. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
6. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci \USA. 1998;95: 10067-10071.
7. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096.
8. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
9. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
10. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
11. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169-6176.
12. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314:537-539.
13. Parker DC. T-cell-dependent B-cell activation. Annu Rev Immunol. 1993;11:331-360.
14. Crawford A, Macleod M, Schumacher T, et al. Primary T-cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol. 2006;176:3498-3506.
15. Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol. 2000;165:5558-5565.
16. Werner-Klein M, Dresch C, Marconi P, et al. Transcriptional targeting of B cells for induction of peripheral CD8 T-cell tolerance. J Immunol. 2007;178:7738-7746.
17. Brodie GM, Wallberg M, Santamaria P, et al. B cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes. 2008;57:909-917.
18. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1:475-482.
19. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B-cell effector cytokines: a role in immune regulation? J Immunol. 2004;172:3422-3427.
20. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008; 222:328-340.
21. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224-1235.
22. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777-1788.
23. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117:574-586.
24. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T-cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
25. De Visser KE, Korets LV, Coussens LM. De novo carcinogen-esis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-423.
26. Neelapu SS, Kwak LW, Kobrin CB, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005;11:986-991.
27. Ritchie DS, Yang J, Hermans IF, et al. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T cells. Scand J Immunol. 2004;60:543-551.
28. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest. 2003;111: 1161-1170.
29. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B-cell dependent. J Immunol. 2004;173:2288-2296. (Pubitemid 39063084)
30. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with inter-feron. N Engl J Med. 2006;354:709-718.
31. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
32. Schmidt M, Bremer E, Hasenclever D, et al. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer. 2007;96:241-247.
33. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol. 2006;176:6434-6442.
34. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol. 2007;179:7365-7375.
35. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.
36. Chen J, Trounstine M, Alt FW, et al. Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus. Int Immunol. 1993;5:647-656.
37. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1994;1:167-178.
38. Van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001;194:481-489.
39. + CD4 T cells. J Immunol. 2007;179:2046-2050.
40. + T-cell colitis through interaction with regulatory T-cell subsets. Proc Natl Acad Sci \USA. 2005;102: 2010-2015.
41. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006;176:705-710.
42. Buhlmann JE, Foy TM, Aruffo A, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity. 1995;2:645-653.
43. Von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006;107:2786-2789.
44. Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66:7741-7747.
45. Watts TH. TNF/TNFR family members in costimulation of T-cell responses. Annu Rev Immunol. 2005;23:23-68.
46. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006;66:4904-4912.